These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 989096)

  • 1. Proximal myopathy caused by latrogenic phosphate depletion.
    Ravid M; Robson M
    JAMA; 1976 Sep; 236(12):1380-1. PubMed ID: 989096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antacid-induced hypophosphatemia: an unusual cause of "pseudo-myopathy".
    Searles RP; Bankhurst AD; Ahlin TD; Messner RP
    J Rheumatol; 1977; 4(2):176-8. PubMed ID: 881694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iatrogenic osteomalacia and myopathy due to phosphate depletion.
    Baker LR; Ackrill P; Cattell WR; Stamp TC; Watson L
    Br Med J; 1974 Jul; 3(5924):150-2. PubMed ID: 4843652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteomalacia and weakness from excessive antacid ingestion.
    Insogna KL; Bordley DR; Caro JF; Lockwood DH
    JAMA; 1980 Dec; 244(22):2544-6. PubMed ID: 7431592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe proximal myopathy in advanced renal failure. Diagnosis and management.
    Adeniyi O; Agaba EI; King M; Servilla KS; Massie L; Tzamaloukas AH
    Afr J Med Med Sci; 2004 Dec; 33(4):385-8. PubMed ID: 15977450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid fall of serum phosphorus secondary to antacid therapy.
    Shields HM
    Gastroenterology; 1978 Dec; 75(6):1137-41. PubMed ID: 710865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure.
    Sherrard DJ; Ott SM; Andress DL
    Am J Med; 1985 Jul; 79(1):127-30. PubMed ID: 4014298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration?
    Andreoli SP; Chesney RW; Salusky IB; Sedman AB
    Pediatr Nephrol; 1990 Jul; 4(4):318. PubMed ID: 2206897
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antacid induction of phosphate depletion syndrome in renal failure.
    Abrams DE; Silcott RB; Terry R; Berne TV; Barbour BH
    West J Med; 1974 Feb; 120(2):157-60. PubMed ID: 4813797
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous repletion of phosphorus deficiency in the chronic renal failure patients with severe hypophosphatemia.
    Chang JM; Tsai JC; Hwang SJ; Chen HC; Guh JY; Lai YH
    Kaohsiung J Med Sci; 1997 Sep; 13(9):540-7. PubMed ID: 9348731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antacid-induced osteomalacia and nephrolithiasis.
    Cooke N; Teitelbaum S; Avioli LV
    Arch Intern Med; 1978 Jun; 138(6):1007-9. PubMed ID: 646554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Moderate' hypophosphatemia--not always an innocent bystander.
    Morris RC
    West J Med; 1987 Nov; 147(5):577-9. PubMed ID: 3424820
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.